The ANZUP Seminal Advances in Prostate Cancer Preceptorship
in collaboration with Monash Institute for Health and Clinical Education (MIHCE)
Date: 3-4 November 2017
Location: Novotel Melbourne Glen Waverley
Convenor: Prof Eva Segelov
Preceptors: Arun Azad, Howard Gurney, George Hruby, Jarad Martin, Declan Murphy, Henry Woo
(read their bios)
Applications are now closed
Applications are now open for the 2017 ANZUP Seminal Advances in Prostate Cancer Preceptorship. Places are limited and expected to fill quickly, applications close Wednesday 30 August 2017.
The 1 ½ day workshop will cover landmark clinical trials in prostate cancer. Our target participants are trainees and junior specialists (first five years of practice) in medical, radiation and surgical oncology. Successful applicants will be supported to attend this exciting initiative.
Areas to be covered include screening, multi-modality management of early, locally advanced and metastatic disease and supportive care.
To apply you must state why you would like to do the course, which papers you would like to present, and have a case study ready to present. The first fully completed applications will be the first to be confirmed. This year, there will be a non-refundable $100 registration fee.
If you are not already a member of ANZUP, please submit a free membership application here (note membership is a condition of attendance).
We look forward to your participation at this interactive learning experience.
About the 2017 Preceptors
||Associate Professor Arun Azad
A/Prof Arun Azad is a medical oncologist and translational researcher specialising in urological cancers. After completing his medical oncology training and a PhD in Melbourne, he completed a fellowship at the internationally renowned Vancouver Prostate Centre. He is currently based at Monash Health and Monash University, where he leads a clinical and translational research program focused on prostate cancer.
||Associate Professor George Hruby
George Hruby completed a fellowship at the Royal Prince Alfred Hospital in 1999 and was awarded a clinical fellowship at the University of Toronto. He spent 13 months in Toronto at a high volume academic centre focused on genito-urinary cancers. In December 2000 he commenced as Staff Specialist in Radiation Oncology at the Royal Prince Alfred Hospital, (now Lifehouse). Clinical milestones have included the establishment of the High Dose Rate brachytherapy program at Royal Prince Alfred Hospital with over 300 implants performed since inception in 2002. Whilst at RPA, George was instrumental in leading the introduction of more sophisticated techniques for the treatment of prostate cancer such as image guided radiation treatment (IGRT) in 2007, IMRT (intensity modulated radiation treatment) for anal cancer in 2009, and for prostate cancer in 2010. In 2014 the first prostate cancer patients were treated with SABR (stereotactic ablative body radiotherapy) for oligo-metastatic disease.
He has mentored and taught radiation oncology registrars as well as medical students, presented at many scientific meetings and co-authored over 75 peer reviewed publications. He currently works at Royal North Shore Hospital where he has established a stereotactic focal prostate re-treatment protocol for those with intra-prostatic recurrence following definitive RT. Other areas of interest include the adoption of PSMA-PET into the GU radiation treatment field.
||Associate Professor Jarad Martin
Jarad Martin is a Radiation Oncologist and departmental Director of Research working at the Calvary Mater Newcastle. He completed his fellowship in 2005 and undertook a genitourinary oncology clinical research fellowship at the Princess Margaret Hospital in Toronto winning the academic excellence in research award from that institution.
His primary clinical and research interests are in urologic and gastrointestinal cancers, including the application of stereotactic radiotherapy for genitourinary tumours. In 2006 he accepted a position in Regional Queensland in Toowoomba and established the Toowoomba Cancer Research Centre (TCRC). Jarad assumed the Australasian Primary Investigator role for the successful PROFIT clinical trial randomising men with prostate cancer to receive either a standard 8 week course or an experimental 4 week regimen of radiotherapy.
Jarad relocated to Newcastle in 2012 and continued to develop a number of senior roles in national bodies. He was the Clinical Liaison for TROG from 2012–15 and was the chair of the Faculty of Radiation Oncology Research Committee from 2011–15. He has been on the executive of the Faculty of Radiation Oncology Genitourinary Group (FROGG) as well as the Scientific Advisory Committee of ANZUP. Jarad has several currently accruing multicentre prospective clinical trials, > 70 peer reviewed publications, and has also recently completed a mid-career PhD.
||Associate Professor Declan G Murphy
Declan Murphy is Consultant Urologist and Director of Genitourinary Oncology at Peter MacCallum Cancer Centre, Melbourne, and Honorary Clinical Associate Professor at the University of Melbourne. He is an internationally-renowned key opinion leader in prostate cancer and robotic surgery. Declan has published hundreds of papers and been Chief Investigator on grants worth many millions of dollars. He holds senior editorial positions at the British Journal of Urology International, European Urology, Nature Reviews Urology, and Prostate Cancer & Prostatic Diseases, and is on the board of reviewers for many other journals. He is also highly active on social media with over 5000 followers on Twitter.
||Professor Henry Woo
Henry Woo is a urological surgeon subspecialised in the treatment of prostate disease. He is Professor of Surgery at the Sydney Adventist Hospital Clinical School of the University of Sydney. He is the Director of Uro-Oncology and the Professor of Robotic Cancer Surgery at the Chris O’Brien Lifehouse. He is also a Board Director of the charitable Australasian Urological Foundation. He is an associate editor of the journal Prostate Cancer Prostate Diseases and serves on the editorial boards of European Urology, BJU International, Asian Journal of Urology and Prostate International.
He regularly reviews manuscripts for major urological journals including European Urology, BJUI, Journal of Urology, Urology, Nature Reviews Urology and Journal of Endourology. He has over 140 publications in peer reviewed journals and several book chapters.
We thank and acknowledge the 2017 Preceptorship sponsors